Blood Coagulation Factor Drug Class List

Drugs in Drug Class: Blood Coagulation Factor

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hospira	TPN ELECTROLYTES IN PLASTIC CONTAINER	calcium chloride; magnesium chloride; potassium chloride; sodium acetate; sodium chloride	INJECTABLE;INJECTION	018895-001	Jul 20, 1984		RX	Yes	Yes
Otsuka Icu Medcl	RINGER'S IN PLASTIC CONTAINER	calcium chloride; potassium chloride; sodium chloride	INJECTABLE;INJECTION	018251-001	Approved Prior to Jan 1, 1982	AP	RX	No	No
B Braun	RINGER'S IN PLASTIC CONTAINER	calcium chloride; potassium chloride; sodium chloride	INJECTABLE;INJECTION	020002-001	Apr 17, 1992	AP	RX	No	No

Market dynamics and patent landscape for drugs in the drug class: Blood Coagulation Factor

Last updated: April 24, 2026

What is the blood coagulation factor market structure?

The “blood coagulation factor” therapeutic area is dominated by replacement therapies for inherited bleeding disorders, most notably hemophilia A (Factor VIII deficiency) and hemophilia B (Factor IX deficiency), plus adjunct or replacement approaches for other coagulation deficiencies and acquired coagulation disorders. Commercial dynamics cluster around (1) route of administration, (2) dosing frequency and prophylaxis convenience, and (3) durability and immunogenicity profiles.

Core commercial segments by product type

Segment	Typical molecule classes	Primary clinical use	Key buying drivers
FVIII replacement	Recombinant factor VIII; extended half-life (EHL) FVIII; single-chain variants	Hemophilia A prophylaxis and on-demand	Dosing interval, bleed control, patient adherence
FIX replacement	Recombinant FIX; EHL FIX; fusion or PEGylated variants; nonacog analogs	Hemophilia B	Dosing interval, imaging and bleeding endpoints
Bypassing agents (mechanistic neighbor market)	Activated prothrombin complex concentrates; activated FVII analogs	Inhibitor patients	Rapid bleed control; inhibitor portfolio breadth
Non-factor approaches (competitive pressure)	Gene therapy; emicizumab (not a factor)	Reduces factor reliance	Shift in long-term economics and churn risk

Even where the drug is “not a coagulation factor” (for example, emicizumab), it competes for the same patient flow and payer budget because it reduces factor use in prophylaxis regimens.

How do major revenue pools move across hemophilia A and B?

Market dynamics have shifted toward EHL products and non-factor prophylaxis, changing how factor manufacturers monetize patients over time.

Key market-moving behaviors

• Treatment migration from standard half-life products to EHL factor concentrates reduces annual injection counts and improves adherence. This pattern drives premium pricing and faster “share turnover” during EHL launches.
• Prophylaxis standardization: payers increasingly require prophylaxis rather than episodic dosing for eligible patients, which raises utilization for products with long dosing intervals.
• Inhibitor management creates durable demand for certain bypass agents and alternative strategies, keeping some non-factor lines resilient.
• Gene therapy adoption risk changes long-horizon revenue expectations. Product switching can occur at the individual patient level when durable one-time treatments become available or when patients reach reimbursement thresholds.

What are the patent landscape anchors for factor VIII and factor IX?

The blood coagulation factor landscape is built on layered IP that typically spans:

• Composition-of-matter claims for the engineered factor (sequence, fusion domain, PEG moiety, stabilization modifications)
• Method claims around manufacture and formulation (including stabilizers and storage conditions)
• Use claims for prophylaxis and dosing regimens
• Process claims for recombinant production systems (cell lines, purification steps)
• Patent “families” that extend protection through late filings in multiple jurisdictions

Patent families are commonly structured to extend exclusivity

For biologics, legal protection depends on jurisdictional frameworks and regulatory exclusivity, but the IP practical effect is the same: manufacturers extend market exclusivity through EHL variants and next-generation molecules rather than relying on a single “first” filing.

Which companies dominate the coagulation factor patent and commercialization footprint?

The market is concentrated among a small set of global players:

• Novo Nordisk (notably hemophilia franchises including factor and non-factor)
• Roche/Genentech (hemophilia prophylaxis via non-factor and partner distribution in certain regions)
• Bioverativ/Sanofi and legacy affiliates (historically significant factor VIII franchise assets and follow-on EHL generations)
• Pfizer (and legacy portfolio) for factor IX and related hemophilia assets and development programs
• CSL Behring for plasma-derived factor products and related technologies

The “patent landscape” is therefore both portfolio-based (each company’s multi-family build) and therapy-line based (prophylaxis regimen claims, EHL selection, and immunogenicity management).

How does the patent landscape typically map to product generations?

For hemophilia factor concentrates, the IP story often proceeds as follows:

1. First-generation recombinant factor: foundational composition and recombinant expression system claims.
2. EHL engineering: additional claims for fusion/PEG/albumin-binding domains or other half-life extension mechanisms.
3. Formulation and stabilization: claims for excipients and storage conditions that support shelf life and handling.
4. Clinical use: prophylaxis dosing interval claims, switching algorithms, and disease subtype refinements.
5. Next-generation analogs: additional sequence variants and manufacturing process improvements to create new patent islands and extend market coverage.

This creates a “staggered” expiration profile where the oldest first-generation patents may expire earlier, while EHL variants and process improvements can extend protection in practice.

What does exclusivity data suggest about the timeline of factor IP coverage?

In the US, regulatory exclusivity interacts with patent expiry through data exclusivity and patent-term mechanisms. For biologics licensed under the BLA pathway, exclusivity under the Biologics Price Competition and Innovation Act (BPCIA) is 12 years of data exclusivity plus potential extensions based on pediatric studies. The FDA also lists regulatory exclusivity and patent-related information in Orange Book and related regulatory records. For biologics, the patent landscape is therefore not only court-driven but also tied to regulatory filings and listing mechanics. Key reference points include FDA’s BPCIA framework and exclusivity durations. (See FDA BPCIA and biologics exclusivity documentation in cited sources.) [1]

How do market dynamics affect R&D and filing strategy?

Pricing and payer pressure changes IP economics

As payers scrutinize total cost of therapy, companies optimize around:

• Prophylaxis interval extensions (fewer administrations)
• Lower annual bleed rate targets with clinical endpoints that support payer contracts
• Switching strategies for previously treated patients (PTPs) to create rapid adoption of new EHL products

These commercialization needs translate into patent filings focused on both molecule features and use claims that can support reimbursement and formulary placement.

Competitive moat shifts from “recombinant factor” to “durability”

The market has moved toward durability and fewer administrations, making half-life extension technology a central IP battleground.

Inhibitor and immunogenicity profiles remain a segmentation lever

Products with better performance in inhibitor populations, or with better immunogenicity handling, can hold out against churn from gene therapy in specific patient subgroups.

Where are the strongest non-factor competitive pressures on factor products?

Emicizumab is a key competitive pressure point because it reduces factor use for many hemophilia A patients and has a dosing regimen that payers can manage. Gene therapy adds a longer-horizon threat: patients treated once may exit the factor market for years. These forces affect factor company patent strategies by shifting incremental R&D toward:

• EHL improvements
• better inhibitor management approaches
• alternative delivery formats (if supported by IP)

How does the regulatory framework shape patent litigation and settlement cadence?

In jurisdictions with patent listing and BLA counterpart processes, the cadence of disputes often follows:

• Patent listing and notice mechanisms
• Litigation or settlement prior to launch of follow-on competitors
• Parallel regulatory filing strategies

In the US specifically, the BPCIA sets the statutory framework for biologics exclusivity and patent dispute timelines. [1]

While most factor products are biologics and there is still limited “biosimilar availability” of complex factor therapies compared with small molecules, the same legal infrastructure affects follow-on biologics and product approvals, and the patent landscape remains central to commercial timing.

What does “patent landscape” mean operationally for investors or R&D leaders?

A usable coagulation factor patent landscape for business decisions should be mapped on three axes:

1. Molecule layer: engineered sequences and half-life extension constructs (composition-of-matter)
2. Product layer: formulation, stability, and administration systems
3. Clinical use layer: prophylaxis regimens, dosing intervals, and clinical protocols that sustain payer coverage

Market actions in hemophilia often hinge on whether a successor product can be marketed at entry points without infringing core composition and use claims, or whether licenses or carve-outs are required.

What are the likely areas of patent expiry and risk?

Without enumerating specific patent numbers or expiration dates per molecule in this response (no jurisdictional patent list is provided), the structural risk areas are:

• Early patents tied to first-generation recombinant factor sequences and basic expression systems
• Narrow process patents that become easier to design around after formulation and purification process evolution
• Method-of-use claims for prophylaxis regimen specifics when those regimens become standard across the class

The primary mitigation typically comes from successor generations (EHL variants) and expanded use claims (new endpoints, new dosing intervals, new patient populations).

How does the competitive landscape connect to market access?

Adoption is governed by contract terms and clinical endpoints

For factor therapies, adoption frequently depends on:

• Bleed reduction outcomes
• adherence improvements from reduced dosing frequency
• real-world persistence metrics
• pharmacokinetic targets (especially for EHL switching)

These become the evidentiary backbone for regulatory submissions and, by extension, the rationale for use-related claims and stewardship of existing IP.

What are the actionable implications for new entrants or partners?

• Partnering strategy: co-develop or acquire engineered half-life extension technologies that can support fresh composition claims, not only incremental manufacturing improvements.
• Positioning strategy: select patient segments most resilient to churn (for example inhibitor cohorts, prophylaxis patients who do not transition to non-factor alternatives, or regions where gene therapy is limited).
• IP diligence: map both composition and use claims, then check whether competitor “evergreening” occurs through incremental formulation or next-generation fusion/PEG constructs.

Key Takeaways

• The blood coagulation factor market is anchored in hemophilia A (FVIII) and hemophilia B (FIX), with durability and dosing interval as the dominant value drivers.
• Patent protection in this class typically stacks across composition-of-matter (engineered factors), product formulation and process, and method-of-use claims for prophylaxis and dosing.
• Competitive dynamics increasingly reduce factor reliance via non-factor prophylaxis (emicizumab) and gene therapy, changing how factor manufacturers build and extend their IP portfolios.
• In the US, biologics exclusivity and the BPCIA framework materially shape the practical exclusivity window and the cadence of patent disputes. [1]

FAQs

1) Which hemophilia markets contribute most to factor VIII and factor IX commercialization?
Hemophilia A (FVIII) and hemophilia B (FIX) drive the core demand for replacement and EHL factor concentrates.

2) What IP elements matter most for factor products?
Composition-of-matter for engineered factors, formulation and manufacturing processes, and method-of-use claims supporting prophylaxis regimens.

3) How do EHL products change the patent landscape?
They create new composition and use claim sets around half-life extension constructs, shifting protection to later-generation patents rather than relying on first-generation expiry.

4) What is the biggest threat to long-term factor utilization?
Non-factor prophylaxis and gene therapy, both of which reduce ongoing factor demand in many patients.

5) How does US regulatory exclusivity interact with patents for biologics?
The BPCIA framework sets biologics data exclusivity periods and a patent dispute mechanism that affects launch timing and litigation leverage. [1]

---

References

[1] U.S. Food and Drug Administration. (n.d.). Biologics Price Competition and Innovation Act (BPCIA) and exclusivity for biologics. FDA. https://www.fda.gov/media/177077/download